Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells
Authors:
Preprint
- 18 December 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
KRAS mutations are significant drivers in various cancers, and existing drug discovery efforts targeting these mutations have largely been unsuccessful, highlighting the need for more effective therapies. In this study, screening library, which contains 1374 chemical compounds, identified Nintedanib, a VEGFR inhibitor, as having a potent and selective antiproliferative effect against KRAS-mutant cells, surpassing other VEGFR inhibitors. Nintedanib effectively suppressed tumor growth in xenografted mice with KRAS mutations and was found to significantly inhibit phosphorylated VEGFR2 levels and its downstream signaling molecules pAKT and pERK in KRAS-mutant cells, suggesting that VEGFR2 inhibition impacts the oncogenic AKT/ERK pathway. Furthermore, in VEGFR2-knockout cells, KRAS-GTP activity was reduced by inhibiting the SOS1 protein, which led to decreased phosphorylation of ERK, AKT, and DRP1, inducing apoptosis. Notably, overexpression of KRASG12D augmented VEGFR2 expression, establishing a positive feedback loop between KRAS mutations and VEGFR2 signaling within the ERK pathway. Immunohistochemical analyses of pancreatic cancer tissues revealed high VEGFR2 expression in 83% (67/80) of samples, significantly exceeding levels observed in normal pancreatic tissues. These findings highlight VEGFR2 as a promising molecular target and propose a novel therapeutic avenue for KRAS-mutant cancers.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic AdenocarcinomaJAMA Network Open, 2025
- DRP1: At the Crossroads of Dysregulated Mitochondrial Dynamics and Altered Cell Signaling in Cancer CellsACS Omega, 2023
- Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancersEuropean Journal of Medicinal Chemistry, 2023
- Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsGenes & Diseases, 2022
- A renal cell carcinoma tumorgraft platform to advance precision medicineCell Reports, 2021
- Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor GrowthCell Reports, 2019
- Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to AntiangiogenicsCell Reports, 2016
- Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor GrowthMolecular Cell, 2015
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysisCell Research, 2011